Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Concord Drugs Ltd.
Source DateBoard Meeting DateDetails
01-Aug-2025 08-Aug-2025 Quarterly Results
30-Jun-2025 03-Jul-2025 Preferential Issue of shares & Increase in Authorised Capital
19-Jun-2025 27-Jun-2025 Preferential Issue of shares & Inter alia, to consider and approve the following business items: 1. To consider and approve the proposal for raising of funds for business expansion purposes, including but not limited to, by way of Preferential Allotment or such other permissible mode(s), subject to necessary approvals. 2. To consider and approve the date, time, and venue for convening an ExtraOrdinary General Meeting of the Company for obtaining shareholders? approval, wherever required. 3. To transact any other matter with the permission of the Chair.
16-May-2025 23-May-2025 Audited Results
13-Mar-2025 17-Mar-2025 Increase in Authorised Capital & Inter alia, to consider and approve: 1. Increase in Authorised Capital 2. Issue of shares on Preferential Allotment 3. Any other matter with the permission of chair
04-Mar-2025 13-Mar-2025 Preferential Issue of shares & Increase in Authorised Capital Inter alia, to consider the following agenda items: 1. Raising of funds for expansion of business and to explore new options by way of issue of Preferential Allotment. 2. Increase in Authorized share Capital and to make subsequent alteration in Memorandum of Association of the Company. 3. Confirmation for Proposed Date, Time and Venue for holding Extra Ordinary General Meeting of the Company. 4. Any other business with the permission of the Chair.
07-Jan-2025 11-Jan-2025 Quarterly Results
06-Nov-2024 13-Nov-2024 Quarterly Results
02-Sep-2024 06-Sep-2024 Increase in Authorised Capital & Preferential Issue of shares
05-Aug-2024 09-Aug-2024 Quarterly Results
24-May-2024 30-May-2024 Audited Results (Revised)
15-May-2024 25-May-2024 Audited Results
06-Feb-2024 13-Feb-2024 Quarterly Results
07-Nov-2023 14-Nov-2023 Quarterly Results
07-Aug-2023 14-Aug-2023 Quarterly Results
09-May-2023 30-May-2023 Audited Results
16-Mar-2023 27-Mar-2023 Inter alia, to consider and approve:- 1. Conversion of warrants into equity shares to the Promoters pursuant to the allotment of the same in the board meeting held on 07.11.2022. 2. Acquisition of Proton Remedies Private Limited as approved by the shareholders in the Annual General Meeting held on 30.09.2022. 3. Any other business with the permission of the Chair.
02-Feb-2023 14-Feb-2023 Quarterly Results
03-Nov-2022 14-Nov-2022 Quarterly Results
05-Sep-2022 07-Sep-2022 Preferential Issue of shares & Inter alia, to consider and approve Raising of funds for expansion of business and to explore new options for inorganic growth.
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.